Kangzhe Pharmaceutical (00867.HK): Performance is lower than expected, and new products are expected to accelerate contributions
Damo: Target price raised to HK$17.8 for Kangzhe Pharmaceutical (00867) “gain” rating
Kangzhe Pharmaceutical (0867.HK): 3 innovative drugs entering health insurance will drive rapid performance growth
Kangzhe Pharmaceutical (0867.HK): Innovation and transformation have begun to reap benefits, pipeline configuration continues to be rich, and long-term growth momentum is strong
Kangzhe Pharmaceutical (00867.HK) Investment Value Analysis Report: Achievement of Change, Innovation, and Fruitful Commercial Platform Pharmaceutical Companies Struggle to Sail
Bank Ratings | Goldman Sachs: Raising Kangzhe Pharmaceutical's target price to HK$18.88 and raising the rating to “buy”
Bank Rating|Goldman Sachs: Raising Kangzhe Pharmaceutical's target price to HK$16.86 and rated “neutral”
Kangzhe Pharmaceutical (00867.HK): The first half of the year was in line with expectations, and management maintained the guidelines for the full year of 2023
Kangzhe Pharmaceutical (00867.HK) Company In-depth Report: Combining Pharmaceutical Innovation and Commercialization with Innovative Drugs and Dermatology and Aesthetics Entering the Harvest Period
Bank Ratings | Lyon: Recent health insurance data from the Mainland shows that good consumption power is optimistic about the growth prospects of the healthcare stock industry
Kangzhe Pharmaceutical (0867.HK): Innovation pipeline enters commercial sales harvest period to fully explore Southeast Asian market policy+economy+demographic dividend
Fangzheng Securities: Kangzhe Pharmaceutical (00867) rated Kangzhe Pharmaceutical (00867) and approved the listing of the first IL-23 antibody in China
Kangzhe Pharmaceutical (00867.HK): The commercialization of tiriqizumab has been approved for marketing in China and is steadily advancing the path of innovation. Results can be expected
Kangzhe Pharmaceutical (0867.HK): Tiriqizumab approved for marketing to start the release of innovative drugs
Kangzhe Pharmaceutical (00867.HK): Steady growth in performance and continuous increase in innovation
Kangzhe Pharmaceutical (00867.HK): Steady performance awaits implementation of innovation and internationalization achievements
Kangzhe Pharmaceutical (0867.HK): Performance continues to grow, 3 innovative drugs will soon be launched
Big Bank Ratings | Lyon: Kangzhe Pharmaceutical raised its target price to HK$14.4 to “buy”
Kangzhe Pharmaceutical (0867.HK): Innovative drugs will be marketed one after another to drive continuous growth in performance
Kangzhe Pharmaceutical (00867.HK): Innovation enters the harvest period, new projects, new market layouts are frequent
No Data